Latest & greatest articles for adhd

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on adhd or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on adhd and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

ADHD

ADHD (or Attention deficit hyperactivity disorder) is a neurodevelopmental type mental disorder. It is characterised two main categories of two types of behavioural problems:

  • inattentiveness
  • hyperactivity and impulsiveness

Most people with ADHD have problems that fall into both categories, but it doesn’t have to be the case. If a person just has inattentiveness it is referred to as attention deficit disorder (ADD).

Methylphenidate is a commonly used medication used to treat patients suffering from attention-deficit hyperactivity disorder. Methylphenidate is part of a group of drugs known as stimulants. Central nervous system stimulants help change the amounts of natural substances in the brain. But it is not the only intervention; others include Bupropion, exercise and CBT (Cognitive behavioural therapy).

Extensive ADHD research and case studies have been carried out over numerous years. Trip has unrivalled coverage of the evidence base including systematic reviews, clinical trials, clinical guidelines and case studies.

Studies are ongoing to assess the safety and effectiveness of stimulants used on children with ADHD and intellectual disabilities as well as in other populations and other interventions. Trip also includes ongoing controlled trials and ongoing systematic reviews (via the PROSPERO database).

Top results for adhd

1. Social skills training for attention deficit hyperactivity disorder (ADHD) in children aged 5 to 18 years. (PubMed)

Social skills training for attention deficit hyperactivity disorder (ADHD) in children aged 5 to 18 years. Attention deficit hyperactivity disorder (ADHD) in children is associated with hyperactivity and impulsivity, attention problems, and difficulties with social interactions. Pharmacological treatment may alleviate the symptoms of ADHD but this rarely solves difficulties with social interactions. Children with ADHD may benefit from interventions designed to improve their social skills. We (...) examined the benefits and harms of social skills training on social skills, emotional competencies, general behaviour, ADHD symptoms, performance in school of children with ADHD, and adverse events.To assess the beneficial and harmful effects of social skills training in children and adolescents with ADHD.In July 2018, we searched CENTRAL, MEDLINE, Embase, PsycINFO, 4 other databases and two trials registers.We also searched online conference abstracts, and contacted experts in the field

2019 Cochrane

2. Methylphenidate remains first-choice drug treatment for children and young people with ADHD

Methylphenidate remains first-choice drug treatment for children and young people with ADHD Methylphenidate remains first-choice drug treatment for children and young people with ADHD Discover Portal Discover Portal Methylphenidate remains first-choice drug treatment for children and young people with ADHD Published on 6 November 2018 doi: The stimulant methylphenidate has the best balance of effectiveness against side effects in children and young people with attention deficit hyperactivity (...) of bias. But this study supports NICE guidance on the range of potential drug options to consider in conjunction with behavioural and support strategies for children and young people with attention deficit hyperactivity disorder. Share your views on the research. Why was this study needed? Attention deficit hyperactivity disorder (ADHD) is a condition that starts in childhood. Symptoms include inattention, hyperactivity and impulsivity that occur at home and school, interfering with functioning

2019 NIHR Dissemination Centre

3. Cognitive behavioural therapy could benefit adults with attention deficit hyperactivity disorder (ADHD)

Cognitive behavioural therapy could benefit adults with attention deficit hyperactivity disorder (ADHD) Cognitive behavioural therapy could benefit adults with ADHD Discover Portal Discover Portal Cognitive behavioural therapy could benefit adults with attention deficit hyperactivity disorder (ADHD) Published on 21 August 2018 doi: Cognitive behavioural therapy improves the core symptoms of attention deficit hyperactivity disorder (ADHD) in adults, compared with a range of other treatments (...) used a variety of outcome measures, which made it difficult to compare the interventions. Despite these limitations, the review provides evidence that reinforces current guidance and practice. Share your views on the research. Why was this study needed? Attention deficit hyperactivity disorder (ADHD) is a group of behavioural symptoms which usually begin in childhood. While the symptoms of inattentiveness, hyperactivity and impulsiveness usually improve with age, they can continue into adulthood

2019 NIHR Dissemination Centre

4. Amphetamines probably the best first-choice treatment for adults with ADHD

Amphetamines probably the best first-choice treatment for adults with ADHD Amphetamines probably the best first-choice treatment for adults with ADHD Discover Portal Discover Portal Amphetamines probably the best first-choice treatment for adults with ADHD Published on 30 October 2018 doi: There is further evidence to support the amphetamines as the most effective group of drugs for treating adults with attention deficit hyperactivity disorder in the short-term. Two of these drugs were shown (...) a quarter of the studies having low risk of bias. The network meta-analysis allowed the authors to compare different drugs with each other as well as with placebos (dummy pills). It strengthens the evidence behind NICE guidelines which recommend a trial of either the amphetamine lisdexamfetamine or another stimulant, methylphenidate, as first-line treatments. Share your views on the research. Why was this study needed? Attention deficit hyperactivity disorder (ADHD) is a persistent pattern

2019 NIHR Dissemination Centre

5. The impact of childhood diagnosed ADHD/ADD versus controls without ADHD/ADD diagnoses on later labor market attachment. - a systematic review of longitudinal studies

The impact of childhood diagnosed ADHD/ADD versus controls without ADHD/ADD diagnoses on later labor market attachment. - a systematic review of longitudinal studies Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability

2019 PROSPERO

6. Placebo effects during treatment with ADHD medications

Placebo effects during treatment with ADHD medications Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith

2019 PROSPERO

7. Effectiveness and safety of Ayurveda intervention in children and adolescent with ADHD: a systematic review with meta-analysis

Effectiveness and safety of Ayurveda intervention in children and adolescent with ADHD: a systematic review with meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

8. Help-seeking behaviours of individuals with symptoms suggestive of attention-deficit/hyperactivity disorder (ADHD): systematic review and narrative synthesis

Help-seeking behaviours of individuals with symptoms suggestive of attention-deficit/hyperactivity disorder (ADHD): systematic review and narrative synthesis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

9. A systematic review of the effectiveness of classwide peer tutoring in improving school performance of school-aged children with ADHD

A systematic review of the effectiveness of classwide peer tutoring in improving school performance of school-aged children with ADHD Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record

2019 PROSPERO

10. Systematic review of pre-injury attention-deficit/hyperactivity disorder (ADHD) as a vulnerability factor for worse outcome following sport-related concussion

Systematic review of pre-injury attention-deficit/hyperactivity disorder (ADHD) as a vulnerability factor for worse outcome following sport-related concussion Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

11. Mindfulness-based intervention and ADHD: outcomes, assessment tools, protocols and efficacy. A systematic review

Mindfulness-based intervention and ADHD: outcomes, assessment tools, protocols and efficacy. A systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated

2019 PROSPERO

12. Meta-analysis of the effects of atomoxetine on executive functioning in patients with attention deficit/hyperactivity disorder (ADHD)

Meta-analysis of the effects of atomoxetine on executive functioning in patients with attention deficit/hyperactivity disorder (ADHD) Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record

2019 PROSPERO

13. ADHD in children and youth: Part 3?Assessment and treatment with comorbid ASD, ID, or prematurity

ADHD in children and youth: Part 3?Assessment and treatment with comorbid ASD, ID, or prematurity Attention-deficit hyperactivity disorder (ADHD) is a chronic neurodevelopmental disorder. Three position statements have been developed by the Canadian Paediatric Society, following systematic literature reviews. Statement objectives are to: 1) Summarize the current clinical evidence regarding ADHD, 2) Establish a standard for ADHD care, and 3) Assist Canadian clinicians in making well-informed (...) , evidence-based decisions to enhance care of children and youth with this condition. Specific topics reviewed in Part 3, which focuses on associated autism spectrum disorder, intellectual disability, and prematurity, include the challenges of diagnostic assessment, common presentations, the role of genetics, and treatment, including the benefits of physical activity. Recommendations are based on current guidelines, evidence from the literature, and expert consensus. Keywords: Autism; ADHD; Intellectual

2018 Canadian Paediatric Society

14. ADHD in children and youth: Part 2?Treatment

ADHD in children and youth: Part 2?Treatment Attention-deficit hyperactivity disorder (ADHD) is a chronic neurodevelopmental disorder. Three position statements have been developed by the Canadian Paediatric Society, following systematic literature reviews. Statement objectives are to: 1) Summarize the current clinical evidence regarding ADHD, 2) Establish a standard for ADHD care, and 3) Assist Canadian clinicians in making well-informed, evidence-based decisions to enhance care of children (...) the literature, and expert consensus. Keywords: ADHD; Adverse effects; Combined interventions; Medication management

2018 Canadian Paediatric Society

15. ADHD in children and youth: Part 1?Etiology, diagnosis, and comorbidity

ADHD in children and youth: Part 1?Etiology, diagnosis, and comorbidity Attention-deficit hyperactivity disorder (ADHD) is a chronic neurodevelopmental disorder. Three position statements have been developed by the Canadian Paediatric Society, following systematic literature reviews. Statement objectives are to: 1) Summarize the current clinical evidence regarding ADHD, 2) Establish a standard for ADHD care, and 3) Assist Canadian clinicians in making well-informed, evidence-based decisions (...) Guidelines Network, and the Eunethydis European ADHD Guidelines Group, were reviewed. Because ADHD is a heterogeneous disorder, comprehensive medical assessment for ADHD should always include a complete history, a physical examination, and a thorough consideration of differential diagnosis and related comorbidities. Specific recommendations for information gathering, testing, and referral are offered. Keywords: Attention-deficit hyperactivity disorder; Comorbidity; Diagnosis; Etiology

2018 Canadian Paediatric Society

16. Nutritional or dietary interventions for children and adolescents with autism spectrum disorder or ADHD

Nutritional or dietary interventions for children and adolescents with autism spectrum disorder or ADHD Nutritional or dietary interventions for children and adolescents with autism spectrum disorder or ADHD We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Swedish Agency for Health Technology Assessment and Assessment of Social Services Nutritional or dietary interventions for children and adolescents with autism spectrum (...) disorder or ADHD Share: Reading time approx. 6 minutes There are theories that different types of nutritional or dietary interventions, where specific food items are excluded from the diet or where nutritional supplements are added, may affect the symptoms of persons with Attention Deficit Hyperactivity Disorder (ADHD) or autism spectrum disorder. This applies, for example, to gluten-free and casein-free diet, ketogenic diet (a strict option of a low carbohydrate diet) or diet where sugar or various

2018 Swedish Council on Technology Assessement

17. Amphetamines for attention deficit hyperactivity disorder (ADHD) in adults. (PubMed)

Amphetamines for attention deficit hyperactivity disorder (ADHD) in adults. Attention deficit hyperactivity disorder (ADHD) is a childhood-onset disorder characterised by inattention, hyperactivity, and impulsivity. ADHD can persist into adulthood and can affects individuals' social and occupational functioning, as well as their quality of life and health. ADHD is frequently associated with other mental disorders such as substance use disorders and anxiety and affective disorders. Amphetamines (...) are used to treat adults with ADHD, but uncertainties about their efficacy and safety remain.To examine the efficacy and safety of amphetamines for adults with ADHD.In August 2017, we searched CENTRAL, MEDLINE, Embase, PsycINFO, 10 other databases, and two trials registers, and we ran citation searches for included studies. We also contacted the corresponding authors of all included studies, other experts in the field, and the pharmaceutical company, Shire, and we searched the reference lists

2018 Cochrane

18. ADHD

ADHD Top results for adhd - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4 (...) ) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for adhd The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted

2018 Trip Latest and Greatest

19. Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders. (PubMed)

Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders. This is an update of the original Cochrane Review published in Issue 4, 2011.Attention deficit hyperactivity disorder (ADHD) is the most prevalent of the comorbid psychiatric disorders that complicate tic disorders. Medications commonly used to treat ADHD symptoms include stimulants such as methylphenidate and amphetamine; non-stimulants, such as atomoxetine; tricyclic (...) antidepressants; and alpha agonists. Alpha agonists are also used as a treatment for tics. Due to the impact of ADHD symptoms on the child with tic disorder, treatment of ADHD is often of greater priority than the medical management of tics. However, for many decades, clinicians have been reluctant to use stimulants to treat children with ADHD and tics for fear of worsening their tics.  OBJECTIVES: To assess the effects of pharmacological treatments for ADHD in children with comorbid tic disorders on symptoms

2018 Cochrane

20. Stimulants for ADHD in children: Revisited

Stimulants for ADHD in children: Revisited Stimulants for ADHD in children: Revisited January - February 2018 Mailing Address: Therapeutics Initiative The University of British Columbia Department of Anesthesiology, Pharmacology & Therapeutics 2176 Health Sciences Mall Vancouver, BC Canada V6T 1Z3 Tel.: 604 822 0700 Fax: 604 822 0701 E-mail: info@ti.ubc.ca www.ti.ubc.ca 110 T his Letter reviews our previous publications and research on this topic and explores whether our publications have led (...) to a change in prescribing of stimulants to children in BC. Despite concerns, stimulant drug treatment of childhood at- tention-deficit/hyperactivity disorder (ADHD) has increased worldwide over the last two decades. 1 The optimal manage- ment of this behavioral condition remains unknown and this is reflected in the wide variation of stimulant treatment by country, jurisdiction, income, race and ethnicity. 1,2 Children are particularly vulnerable to harms of long- term drug therapies and there should

2018 Therapeutics Letter